Abstract 5402
Background
Colorectal cancers with microsatellite instability (MSI) are associated with abundance of tumour infiltrating lymphocytes (TILs). Recent studies have shown that a proportion of TILs may actually be resident memory T cells, not just a continuous circulation of T cells.
Methods
Patients with known MSI and BRAF status were eligible for inclusion in this study. Histopathology slides prepared with haematoxylin and eosin were reviewed using an Olympus BX53 microscope to examine the tumour invading edge and core. These slides were then scanned electronically and reexamined with both the investigator and a pathologist. Blocks from these representative slides were recut using a microtome in preparation for quantitative multiplex immunofluorescence staining. All immunofluorescence staining was carried out on 4-µm-thick sections using an Autostainer Plus (Dako – Agilent Technologies) with appropriate positive and negative controls. Opal Multiplex IHC Assay kit (PerkinElmer) was used. Statistical analysis was performed using Graphpad Prism Version 7 and Stata Version 15.
Results
72 patients with known MSI and BRAF status were eligible for inclusion in this study. 36 of these patients were successfully underwent quantitative multiplex immunofluorescence staining. Overall, there was a statistically significant increase in T cells in the MSI BRAF mutant and wild type group over the MSS group. There was a statistically significant difference in Trm between MSI-H BRAF mutant vs. MSS (mean/mm2: 2.922 (2.4239-3.4201) vs. 0.9854 (0.8162-1.1546) p = 0.0002). There was also a statistically significant difference between MSI-H BRAF wt vs. MSS (mean/ mm2: 2.119 (1.7603-2.4777) vs. 0.9854 (0.8162-1.1546) p = 0.0002). The difference between MSI-H BRAF mutant and wild type was not statistically significant.
Conclusions
This study has shown that resident memory T cells are in greater abundance in MSI-H colorectal cancers compared to their MSS counterpart. Trms may play a role in the immunogenicity of MSI-H colorectal cancers, and may be a target for immune-related therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5458 - Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120 mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen.
Presenter: Philippe Ruszniewski
Session: Poster Display session 2
Resources:
Abstract
1234 - Analysis of PD-1/PD-L1 blockade biomarker and immune infiltrates in Gastroenteropancreatic neuroendocrine carcinoma
Presenter: Jia Zhang Xing
Session: Poster Display session 2
Resources:
Abstract
1517 - Diabetes Is Associated With Pancreatic Neuroendocrine Tumors Growth and Metastasis
Presenter: Zhiyao Fan
Session: Poster Display session 2
Resources:
Abstract
2145 - Investigation of the reclassification of G1/G2 pancreatic neuroendocrine neoplasms by WHO 2017 classification
Presenter: Takahiro Yokose
Session: Poster Display session 2
Resources:
Abstract
3134 - Treatment with somatostatin analogues after radiopeptide therapy
Presenter: Daria Handkiewicz Junak
Session: Poster Display session 2
Resources:
Abstract
2191 - Safety and Tolerability of Surufatinib in Western Patients with Solid Tumors
Presenter: Erika Hamilton
Session: Poster Display session 2
Resources:
Abstract
3253 - The impact of tumour absorbed dosimetry with survival outcomes after peptide receptor radionuclide therapy in metastatic neuroendocrine tumours.
Presenter: Rahul Ladwa
Session: Poster Display session 2
Resources:
Abstract
3581 - Opportunist and Serious Infections in Patients with Neuroendocrine Tumors Treated With Everolimus: A Multicenter Study of Real World Patients
Presenter: Carine Mauro
Session: Poster Display session 2
Resources:
Abstract
5374 - Establishment of Prognostic Nomogram Based on the Metastatic Lymph Nodes Ratio for Patients with Gastric Neuroendocrine Tumour
Presenter: yaobin lin
Session: Poster Display session 2
Resources:
Abstract
3951 - Neutrophil-lymphocyte ratio as an independent predictive factor in Neuroendocrine Neoplasms
Presenter: Sofia Ferreira
Session: Poster Display session 2
Resources:
Abstract